AB Science S.A. (0Q77.L)
EUR 1.44
(0.14%)
EUR 1.44
(0.14%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 16.98 Million EUR | -11.95% |
| 2022 | 19.29 Million EUR | 149.81% |
| 2021 | 7.72 Million EUR | 231.74% |
| 2020 | 2.32 Million EUR | 38.24% |
| 2019 | 1.68 Million EUR | 15209.09% |
| 2018 | 11 Thousand EUR | -99.88% |
| 2017 | 9.33 Million EUR | -24.49% |
| 2016 | 12.35 Million EUR | -43.56% |
| 2015 | 21.89 Million EUR | -3.07% |
| 2014 | 22.59 Million EUR | 2.4% |
| 2013 | 22.06 Million EUR | 1397.69% |
| 2012 | 1.47 Million EUR | 0.0% |
| 2011 | - EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 2.83 Million EUR | 0.0% |
| 2023 FY | 16.98 Million EUR | -11.95% |
| 2023 Q2 | 17.27 Million EUR | -3.04% |
| 2023 Q4 | 16.98 Million EUR | 0.54% |
| 2023 Q3 | 16.89 Million EUR | -2.18% |
| 2023 Q1 | 17.81 Million EUR | -7.66% |
| 2022 Q1 | 20.03 Million EUR | 159.43% |
| 2022 Q3 | 23.04 Million EUR | 47.01% |
| 2022 Q4 | 19.29 Million EUR | -16.28% |
| 2022 FY | 19.29 Million EUR | 149.81% |
| 2022 Q2 | 15.67 Million EUR | -21.76% |
| 2021 Q2 | 7.98 Million EUR | -4.08% |
| 2021 Q3 | 14.44 Million EUR | 80.89% |
| 2021 FY | 7.72 Million EUR | 231.74% |
| 2021 Q4 | 7.72 Million EUR | -46.53% |
| 2021 Q1 | 8.32 Million EUR | 257.6% |
| 2020 Q2 | 1.53 Million EUR | -90.24% |
| 2020 Q4 | 2.32 Million EUR | -84.66% |
| 2020 Q1 | 15.73 Million EUR | 834.62% |
| 2020 Q3 | 15.17 Million EUR | 887.83% |
| 2020 FY | 2.32 Million EUR | 38.24% |
| 2019 Q2 | 1.23 Million EUR | -89.58% |
| 2019 Q4 | 1.68 Million EUR | -88.0% |
| 2019 Q3 | 14.02 Million EUR | 1037.71% |
| 2019 Q1 | 11.83 Million EUR | 107463.63% |
| 2019 FY | 1.68 Million EUR | 15209.09% |
| 2018 Q2 | 9.33 Million EUR | 17.05% |
| 2018 FY | 11 Thousand EUR | -99.88% |
| 2018 Q4 | 11 Thousand EUR | -99.87% |
| 2018 Q3 | 8.2 Million EUR | -12.08% |
| 2018 Q1 | 7.97 Million EUR | -14.56% |
| 2017 Q3 | 11.05 Million EUR | 18.42% |
| 2017 Q4 | 9.33 Million EUR | -15.56% |
| 2017 Q1 | 12.13 Million EUR | -1.8% |
| 2017 Q2 | 9.33 Million EUR | -23.11% |
| 2017 FY | 9.33 Million EUR | -24.49% |
| 2016 Q1 | 13.19 Million EUR | -39.76% |
| 2016 FY | 12.35 Million EUR | -43.56% |
| 2016 Q4 | 12.35 Million EUR | 0.0% |
| 2016 Q3 | 12.35 Million EUR | -6.3% |
| 2016 Q2 | 13.18 Million EUR | -0.01% |
| 2015 Q4 | 21.89 Million EUR | -0.0% |
| 2015 FY | 21.89 Million EUR | -3.07% |
| 2015 Q3 | 21.89 Million EUR | -4.95% |
| 2015 Q1 | 23.03 Million EUR | 1.98% |
| 2015 Q2 | 23.03 Million EUR | 0.0% |
| 2014 Q4 | 22.59 Million EUR | 0.0% |
| 2014 Q2 | 22.32 Million EUR | 0.0% |
| 2014 Q1 | 22.32 Million EUR | 1.17% |
| 2014 FY | 22.59 Million EUR | 2.4% |
| 2014 Q3 | 22.59 Million EUR | 1.21% |
| 2013 Q1 | 21.98 Million EUR | 1392.26% |
| 2013 Q2 | 21.98 Million EUR | 0.0% |
| 2013 Q3 | 22.06 Million EUR | 0.36% |
| 2013 Q4 | 22.06 Million EUR | 0.0% |
| 2013 FY | 22.06 Million EUR | 1397.69% |
| 2012 Q4 | 1.47 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 1.47 Million EUR | 0.0% |
| 2011 FY | - EUR | 0.0% |
| 2011 Q4 | - EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | 5.41 Million EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Boiron SA | 6.64 Million EUR | -155.651% |
| Laboratorios Farmaceuticos Rovi, S.A. | 38.57 Million EUR | 55.961% |
| Vetoquinol SA | 9.66 Million EUR | -75.805% |
| Valneva SE | 132.76 Million EUR | 87.205% |
| Nanobiotix S.A. | 41.66 Million EUR | 59.222% |
| PHAXIAM Therapeutics S.A. | 7.03 Million EUR | -141.65% |
| Vivoryon Therapeutics N.V. | - EUR | -Infinity% |
| BioSenic S.A. | 15.57 Million EUR | -9.086% |
| ABIVAX Société Anonyme | 44.69 Million EUR | 61.993% |
| Formycon AG | 7.81 Million EUR | -117.377% |